Rifat Emral1, Faruque Pathan2, Carlos Augusto Yepes Cortés3, M Hesham El-Hefnawy4, Su-Yen Goh5, Ana Maria Gómez6, Angela Murphy7, Salah Abusnana8, Achmad Rudijanto9, Anand Jain10, Zhulin Ma11, Roberto Mirasol12. 1. Ankara University, Faculty of Medicine, Department of Endocrinology and Metabolic Diseases, Ankara, Turkey. Electronic address: rifatemral@yahoo.com. 2. BIRDEM Hospital, Dhaka, Bangladesh. Electronic address: pathan279@yahoo.com. 3. Department of Internal Medicine and Endocrinology, Hospital Universitario Clínica San Rafael, Bogotá, Colombia. Electronic address: yepes.augusto@gmail.com. 4. National Institute of Diabetes and Endocrinology, Cairo, Egypt. Electronic address: drhefnawy@yahoo.com. 5. Singapore General Hospital, Singapore. Electronic address: goh.su.yen@sgh.com.sg. 6. Department of Internal Medicine and Endocrinology, Medical Faculty of Javeriana University, Head of Endocrinology Unit, San Ignacio Hospital, Bogotá, Colombia. Electronic address: amgomez@javeriana.edu.co. 7. Sunward Park Centre for Diabetes Excellence, Boksburg, South Africa. Electronic address: physician@sunwardparkmedical.co.za. 8. Rashid Center for Diabetes and Research, Al Jurf Ajman, Ajman, United Arab Emirates. Electronic address: salah.abusnana@rcdr.ae. 9. Department of Internal Medicine, Medical Faculty of Brawijaya University, Kota Malang, Jawa Timur 65145, Indonesia. Electronic address: achmadrudijanto@yahoo.co.id. 10. Novo Nordisk Region International Operations AG, Zurich, Switzerland. Electronic address: ajai@novonordisk.com. 11. Novo Nordisk Region International Operations AG, Zurich, Switzerland. Electronic address: joli.mzl@gmail.com. 12. Section of Endocrinology, Diabetes and Metabolism, St. Luke's Medical Center, Quezon City, Philippines. Electronic address: mirasolroberto@gmail.com.
Abstract
AIMS: Hypoglycemia constitutes a significant barrier to achieving glycemic control with insulin in both type 1 and type 2 diabetes. Historically, it has been difficult to accurately verify the rates of hypoglycemia within a clinical setting and there is a need for high-quality, real-world data to ascertain the true rates of hypoglycemia in clinical practice. The global Hypoglycemia Assessment Tool (HAT) study was designed to assess the global incidence of hypoglycemia in patients with insulin-treated diabetes, and the results have indicated that the overall incidence of hypoglycemia is high, with large variations between geographical regions. METHODS: The International Operations HAT (IO HAT) study retrospectively and prospectively assessed the incidence of hypoglycemia in patients with insulin-treated diabetes in Bangladesh, Colombia, Egypt, Indonesia, Philippines, Singapore, South Africa, Turkey, and United Arab Emirates. RESULTS: During the prospective period, hypoglycemic events were reported by 97.4% of patients with type 1 diabetes and 95.3% of those with type 2 diabetes, with an estimated rate of 6.86 events per patient per month (PPPM) for patients with type 1 diabetes and 2.37 events PPPM for patients with type 2 diabetes. CONCLUSIONS: These results represent the first patient-reported dataset on hypoglycemia in the participating countries and confirm that hypoglycemia is under-reported and more widespread than previously believed. Although the incidence of hypoglycemia was variable among patients on different treatment regimens, there were substantial impacts on both productivity and healthcare utilization following an episode of hypoglycemia. This trial is registered at clinicaltrials.gov: NCT02306681.
AIMS: Hypoglycemia constitutes a significant barrier to achieving glycemic control with insulin in both type 1 and type 2 diabetes. Historically, it has been difficult to accurately verify the rates of hypoglycemia within a clinical setting and there is a need for high-quality, real-world data to ascertain the true rates of hypoglycemia in clinical practice. The global Hypoglycemia Assessment Tool (HAT) study was designed to assess the global incidence of hypoglycemia in patients with insulin-treated diabetes, and the results have indicated that the overall incidence of hypoglycemia is high, with large variations between geographical regions. METHODS: The International Operations HAT (IO HAT) study retrospectively and prospectively assessed the incidence of hypoglycemia in patients with insulin-treated diabetes in Bangladesh, Colombia, Egypt, Indonesia, Philippines, Singapore, South Africa, Turkey, and United Arab Emirates. RESULTS: During the prospective period, hypoglycemic events were reported by 97.4% of patients with type 1 diabetes and 95.3% of those with type 2 diabetes, with an estimated rate of 6.86 events per patient per month (PPPM) for patients with type 1 diabetes and 2.37 events PPPM for patients with type 2 diabetes. CONCLUSIONS: These results represent the first patient-reported dataset on hypoglycemia in the participating countries and confirm that hypoglycemia is under-reported and more widespread than previously believed. Although the incidence of hypoglycemia was variable among patients on different treatment regimens, there were substantial impacts on both productivity and healthcare utilization following an episode of hypoglycemia. This trial is registered at clinicaltrials.gov: NCT02306681.
Authors: Salah Abusnana; Salem A Beshyah; Nawal Al-Mutawa; Rima Tahhan; Mahir Jallo; Ravi Arora; Hazem Aly; Sagar Singhal Journal: Sultan Qaboos Univ Med J Date: 2019-03-28
Authors: Md Faruque Pathan; M Fariduddin; Khwaja Nazimuddin; Abdus Saleque Mollah; Md Nazrul Islam Siddiqui; Kazi Ali Hassan; H S Ferdous; Muhammad Hafizur Rahman; S M Ashrafuzzaman; Md Javed Sobhan; Md Reza E-Tanvir Haider; Mohammod Feroz Amin Journal: Indian J Endocrinol Metab Date: 2018 May-Jun
Authors: Guillermo Guzmán; Veline Martínez; Julián David Yara; Miguel Angel Mina; Juan Sebastian Solarte; Angela María Victoria; Karen Fériz Journal: J Diabetes Res Date: 2020-08-05 Impact factor: 4.011
Authors: Stephané Roze; Jayne Smith-Palmer; Simona de Portu; Alexis Delbaere; Bonnie de Brouwer; Harold W de Valk Journal: Clinicoecon Outcomes Res Date: 2019-01-14